Predicting the onset of multiple myeloma in at-risk individuals
Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation
This study is looking for people who might be at risk of developing multiple myeloma, a type of blood cancer, by checking for early signs of a related condition called MGUS, so we can find better ways to catch it early and help patients get the treatment they need.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10906223 on NIH RePORTER |
What this research studies
This research focuses on identifying individuals at high risk for developing multiple myeloma (MM), a type of blood cancer that often starts with a precursor condition called monoclonal gammopathy of undetermined significance (MGUS). By screening a diverse population for early signs of this condition, the study aims to improve early detection and treatment options. The research utilizes advanced mass spectrometry techniques to analyze blood samples and identify biomarkers associated with the progression from MGUS to MM. This proactive approach could lead to timely interventions that enhance patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals over 50 years old, particularly those who are Black or have a family history of hematologic malignancies.
Not a fit: Patients who are younger than 50 and do not have any known risk factors for multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis and treatment of multiple myeloma, potentially improving survival rates and reducing complications.
How similar studies have performed: Previous studies have shown success in early detection and intervention strategies for hematologic malignancies, indicating a promising avenue for this research.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Ghobrial, Irene M. — Dana-Farber Cancer Inst
- Study coordinator: Ghobrial, Irene M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.